The draft E6(R3), that is revision 3, of the Good Clinical Practice guideline was released as draft for Consultation on 19 May by the ICH Assembly after completion by the Expert Working Group. Expect countries globally to release it for comment also - but that will take time. Those involved in any aspect of clinical trials should assess the revision to the GCPs to assess what has changed, but not act yet to change their practices as the final guidance will surely contain some differences. The volume of comments will be high given the topic and content; which runs to 73 pages with Appendices.
Information and interesting ideas
Topics posted here will be in the realm of bioanalysis and biomarkers as part of new therapeutic development, with the occasional post of scientific topics that I find interesting.
Subscribe to:
Post Comments (Atom)
FDA and CMS issue statement on LDTs: Americans Deserve Accurate and Reliable Diagnostic Tests, Wherever They Are Made
This joint statement notes the evolution of Laboratory Developed Tests (LDTs) from the initial rule and approach the FDA had for oversite, a...
-
FDA has released an app - " Drugs@FDA includes most of the drug products approved since 1939. The majority of patient information, l...
-
Post-BREXIT, the UKs MHRA joined ICH as an independent body in May 2022. This notification on the Agency's Blog provides an overview o...
-
If you have or haven't looked at the ICH E6 revision 3 GCP guideline, this may be of interest to see how others perceive the difference...
No comments:
Post a Comment